Compare WULF & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WULF | AMPH |
|---|---|---|
| Founded | 1952 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 1.2B |
| IPO Year | 1995 | 2014 |
| Metric | WULF | AMPH |
|---|---|---|
| Price | $12.54 | $27.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | $16.71 | ★ $31.00 |
| AVG Volume (30 Days) | ★ 34.9M | 396.5K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.27 |
| Revenue | $167,604,000.00 | ★ $723,305,000.00 |
| Revenue This Year | $33.36 | $1.35 |
| Revenue Next Year | $124.75 | $5.10 |
| P/E Ratio | ★ N/A | $11.72 |
| Revenue Growth | ★ 30.58 | N/A |
| 52 Week Low | $2.06 | $20.39 |
| 52 Week High | $17.05 | $40.74 |
| Indicator | WULF | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 44.60 | 57.96 |
| Support Level | $11.32 | $25.16 |
| Resistance Level | $13.64 | $26.50 |
| Average True Range (ATR) | 1.27 | 0.85 |
| MACD | -0.32 | 0.03 |
| Stochastic Oscillator | 22.47 | 80.63 |
TeraWulf Inc is a digital asset technology company that is engaged in digital infrastructure and sustainable energy development. It is involved in supporting environmentally conscious bitcoin mining operations by developing and operating facilities within the United States. The company's bitcoin mining facilities are powered by clean, affordable, and reliable energy sources. Its primary source of revenue stems from the mining of bitcoin conducted at the company's mining facility sites. Additionally, the company occasionally generates revenue through the provision of miner hosting services to third-party entities.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.